Dec 03, 2024
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
Nov 27, 2024
Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List
Nov 24, 2024
Innovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024
Oct 28, 2024
Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics
Oct 16, 2024
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint
Oct 07, 2024
Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
Sep 26, 2024
Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis
Sep 17, 2024
Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress
Sep 17, 2024
Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 2024 ESMO Congress
Sep 10, 2024
Innovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLC
Sep 09, 2024
Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation
Sep 01, 2024
Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024
Aug 28, 2024
Innovent Announces 2024 Interim Results and Business Updates
Aug 28, 2024
Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024
Aug 21, 2024
China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China
Aug 01, 2024
Innovent Announces the NDA of Mazdutide for Type 2 Diabetes has been Accepted by the NMPA of China
Jul 25, 2024
Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
Jul 07, 2024
Innovent Launches Environmental, Social and Governance (ESG) Website to Advance Sustainability and Corporate Responsibility
Jul 05, 2024
Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy
Jul 01, 2024
Innovent Announces Oral Presentation at the ESMO Gastrointestinal Cancers Congress 2024 on Latest Clinical Data of Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma